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ABSTRACT 	  The	   tumor	   suppressor	   p53	   is	   a	   transcriptional	   factor	   which	   is	   frequently	  inactivated	   in	   cancer,	   either	   by	   point	   mutations	   or	   by	   its	   negative	   regulators,	  such	  as	  Mdm2	  and	  MdmX.	  Reactivation	  of	  p53	  by	  small	  molecules	  is	  a	  promising	  strategy	   to	   treat	   	   cancer.	   The	   aim	   of	   this	   thesis	   is	   to	   elucidate	   the	   molecular	  mechanisms	   of	   the	   different	   biological	   responses	   induced	   by	   two	   p53-­‐reactivating	  small	  molecules,	  RITA	  and	  nutlin.	  	  We	  found	  that	  the	  induction	  of	  p53	  pro-­‐apoptotic	  target	  genes	  is	  not	  sufficient	  to	  induce	  a	  full-­‐scale	  cell	  death;	  the	  inhibition	  of	  key	  survival	  genes	  is	  necessary	  to	  trigger	   robust	   apoptosis	   upon	   reactivation	   of	   p53.	   Our	   results	   reveal	   that	   two	  distinct	   transcriptional	   programs,	   activation	   of	   pro-­‐apoptotic	   genes	   and	  repression	   of	   pro-­‐survival	   genes	   are	   required	   to	   be	   orchestrated	   by	   p53	   to	  produce	   a	   robust	   apoptotic	   outcome.	   In	   contrast	   to	   p53-­‐mediated	  transactivation,	  transrepression	  by	  p53	  is	  more	  strictly	  controlled	  by	  Mdm2	  and	  requires	  a	  high	  ratio	  of	  p53/Mdm2	  at	  the	  promoters	  of	  repressed	  genes.	  	  Further	  investigation	  of	  the	  underlying	  mechanisms	  of	  the	  differential	  biological	  outcome	   upon	   p53	   reactivation	   revealed	   that	   the	   inhibition	   of	   TrxR1	   by	   RITA	  leads	   to	   the	   induction	   of	   ROS	   and	   activation	   of	   JNK.	   Activated	   JNK	   creates	   a	  positive	   feedback	   loop	   with	   p53	   and	   converts	   p53	   into	   an	   efficient	  transrepressor.	   We	   demonstrated	   that	   Wip1	   is	   one	   of	   the	   crucial	   factors	  downstream	   of	   JNK,	   whose	   inhibition	   contributes	   to	   a	   robust	   and	   sustained	  transcriptional	  response	  by	  p53	  and	  the	  subsequent	  cell	  death.	  Our	  data	  suggest	  that	   simultaneous	   activation	   of	   p53	   and	   inhibition	   of	   TrxR1	   lead	   to	   synthetic	  lethality	  in	  cancer	  cells.	  Our	  study	  points	  out	  that	  perturbing	  the	  redox	  system	  in	  tumors,	   which	   carry	   abnormally	   high	   level	   of	   ROS,	   might	   enable	   the	  pharmacologically	  reactivated	  p53	  to	  selectively	  eliminate	  cancer	  cells.	  	  Neuroblastoma	   is	  one	  of	   the	  most	  challenging	  childhood	  cancers.	  The	  ability	  of	  RITA	  to	  reactivate	  both	  wild	  type	  and	  mutant	  p53	  prompted	  us	  to	  investigate	  the	  effect	   of	   RITA	   in	   a	   panel	   of	   seven	   neuroblastoma	   cell	   lines	  with	   different	   p53	  status.	  We	  found	  that	  RITA	  induced	  apoptosis	  in	  all	  the	  neuroblastoma	  cell	  lines	  tested,	  irrespective	  of	  the	  status	  of	  p53.	  RITA-­‐activated	  p53	  induced	  a	  set	  of	  pro-­‐apoptotic	   target	   genes.	   In	   addition,	   RITA-­‐activated	   p53	   repressed	   several	   key	  survival	   genes,	   including	  N-­‐myc,	  Wip1,	   Aurora	   kinase,	  Mcl-­‐1,	   Bcl-­‐2,	  Mdm2	   and	  MdmX.	  Moreover,	  RITA	  exhibited	  strong	  antitumor	  effect	  in	  xenograft	  models.	  	  In	  summary,	  our	  data	  presented	  above	  demonstrate	  that	  concurrent	  activation	  of	  p53	   in	   combination	  with	   inhibition	  of	  TrxR1	   followed	  by	   the	   induction	  of	  ROS	  represent	  a	  promising	  strategy	   to	   treat	  cancer.	   Inhibition	  of	  pro-­‐survival	  genes	  plays	  a	  fundamental	  role	  in	  a	  full-­‐scale	  apoptosis	  induction	  in	  cancer	  cells	  upon	  pharmacological	  p53-­‐reactivation.	  
